Clinical trials
Advanced Malignancies clinical trials
Below are recruiting advanced malignancies clinical trials, each written for real people, not researchers. We’re tracking 320 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06410092RecruitingPhase 1
Safety study of FTL001 for advanced solid tumors
This trial tests a new drug called FTL001 for people with advanced solid tumors that have not improved with standard therapy. The goal is to see if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18–75 - NCT06413953RecruitingPhase 1
Testing TQB3107 for advanced solid tumors
This trial is testing a new oral medication called TQB3107 for people with advanced solid tumors (cancer that has spread or cannot be removed). The study aims to see if the drug is safe and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT06281678RecruitingPhase 2
Study of IBI363 for advanced solid tumors
This trial tests a new drug called IBI363 for people with advanced solid tumors. It aims to see if the drug is safe and effective. You may be able to join if you are generally well and have not had other cancer treatments recently.
San Francisco, CaliforniaAges 18 years+ - NCT05391490RecruitingPhase 1
Testing donated immune cells for advanced CD19 blood cancers
This early-phase trial tests donated (allogeneic) immune cells engineered to recognize CD19, a target found on many B-cell cancers. It’s designed for people whose CD19+ cancer has come back or didn’t respond after several previous treatments, aiming to shrink tumors and control disease.
LondonAges 16–65 - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120 - NCT06228326RecruitingPhase 1/Phase 2
Study of KB707 for advanced cancers affecting the lungs
This trial tests a new medicine called KB707 for people with advanced cancers that affect the lungs. It uses a virus to deliver a gene that may help your immune system fight the tumor. The study is especially looking at people with lung cancer (NSCLC) or other solid tumors that have spread to the lungs and haven't responded to standard treatments.
Dothan, AlabamaAges 18 years+ - NCT07287995RecruitingPhase 1/Phase 2
Study of ASP2998 alone or with other therapies for solid tumors
This trial tests a new drug, ASP2998, given alone or with standard cancer treatments for people with advanced solid tumors, including certain types of lung, bladder, stomach, and breast cancers. The goal is to see if ASP2998 can help when other treatments have stopped working or are not an option.
Hackensack, New JerseyAges 18 years+ - NCT07282262RecruitingPhase 2
Ivosidenib for advanced bile duct cancer with IDH1 mutation
This trial tests the drug Ivosidenib for people with advanced bile duct cancer that has a specific genetic change called an IDH1 mutation. It may be an option if you haven't had chemotherapy yet or if your cancer returned more than 6 months after surgery.
BeijingAges 18–80 - NCT07112222RecruitingPhase 1/Phase 2
Study of LM-350 for advanced solid tumors
This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
Wollongong, New South WalesAges 18 years+ - NCT06770569RecruitingPhase 1
Study of HRS-3802 for advanced solid tumors
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
Saint Leonards, New South WalesAges 18 years+ - NCT06737731RecruitingPhase 1/Phase 2
SHR-1681 for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called SHR-1681 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to see if it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07567222RecruitingPhase 1
Vaccine therapy for advanced solid tumors
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
Chengdu, SichuanAges 18–75 - NCT06543069RecruitingPhase 2
Combination therapy for unresectable peritoneal mesothelioma
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
BeijingAges 18 years+ - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Birmingham, AlabamaAges 18 years+ - NCT06051760RecruitingPhase 1
NV-001 for advanced solid tumors after standard treatments
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT05918445RecruitingPhase 1/Phase 2
PM8002 for advanced solid tumors that have stopped responding
This Phase 1/2 study tests PM8002 in people with advanced solid cancers to see if it can work and is safe. It may help if your cancer has measurable disease and you have not fully recovered from side effects of prior treatment.
BaojiAges 18–75 - NCT04116541RecruitingPhase 2
Targeted therapy for advanced cancer based on tumor genetics
This trial tests different targeted therapies based on the unique genetic changes in your tumor. It is for people with advanced or metastatic cancer who have exhausted standard options and whose tumor has specific genetic markers matched to one of the study drugs.
AngersAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT07631793RecruitingPhase 1
Experimental vaccine for advanced solid tumors
This trial tests an experimental vaccine called YKYY031 for people with advanced solid tumors that have stopped responding to standard treatments. The vaccine aims to help your immune system fight cancer cells that carry specific markers. It may be an option if you have certain genetic markers and tumor proteins.
Beijing, Beijing MunicipalityAges 18–75 - NCT07785609RecruitingPhase 2
New drug combination for advanced solid tumors
This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.
San Antonio, TexasAges 18 years+ - NCT07505771RecruitingPhase 1
A study of 177Lu-IM-3050 for advanced solid tumors
This trial tests a new treatment called 177Lu-IM-3050 for people with advanced solid tumors that have not responded to or stopped working with standard treatments. The treatment targets a protein called FAP found on some cancer cells and may help shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT07022002RecruitingPhase 2
Testing a new drug for HER2-positive advanced cancers
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07339085Recruiting
Advanced MRI for brain tumor recurrence or radiation damage
This study uses advanced MRI scans to better tell the difference between a returning brain tumor and radiation injury. It may help guide your treatment decisions.
Los Angeles, CaliforniaAges 18 years+ - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Duarte, CaliforniaAges 18 years+
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignancies?
- Yes. Clin2 currently lists 320 recruiting advanced malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.